Article

ASCRS 2020: Eyevance portfolio brimming with product launches

Author(s):

Alex Delaney-Gesing
Conferences|ASCRS

Ophthalmology Times' Sheryl Stevenson speaks with Julie Speed, chief commercial officer of Eyevance Pharmaceuticals, on what's on the agenda for the company's porfolio this year with product launches during the 2020 ASCRS virtual meeting.
 

 

See more ASCRS coverage here

Related Videos
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Related Content
ASCRS looks forward during milestone meeting
May 20th 2024

ASCRS looks forward during milestone meeting

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
July 26th 2021

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

Liver function test changes after fungal keratitis treatment
April 7th 2024

Liver function test changes after fungal keratitis treatment

EyePod
June 17th 2020

ASCRS 2020: Assessing aberration of monofocal toric IOL with enhanced optic recovery, alignment

Measuring biomarkers may Identify patients at risk of retinal vascular progression after cataract surgery
April 7th 2024

Measuring biomarkers may Identify patients at risk of retinal vascular progression after cataract surgery

Possible role of face masks in increased incidence of infectious keratitis after PRK during COVID
April 6th 2024

Possible role of face masks in increased incidence of infectious keratitis after PRK during COVID

© 2025 MJH Life Sciences

All rights reserved.